Search This Blog

Friday, 7 June 2019

CANCER IS NOT A DISEASE; It's Big Business! 9.6million cancer deaths in 2018.


Global Cancer 2018 Estimates:
18.1 Million Cancer Cases
And 9.6 Million deaths!

“Cancer is not a disease;
It’s Big Business!

(M. Javed Naseem)


With immense technological advancement and new inventions, our society is slowly becoming addicted to the artificial comforts of life. In reality, we are becoming sick both physically and morally. Corruption and injustice are all over the world, in every sphere of life, and everybody is looking for peace and happiness. Technological development has poisoned our food-grains, crops, vegetables and fruits genetically and along with that also the fertilizers. When these two sides attack and we get sick, we seek relief in the third one, which is medicine. Unfortunately, the medication helps less with the cure of our ailment but spreads the diseases, actually diseases, being the side-effects. We are trapped in a death-trap by the Big Pharma.

First, it was AIDS; then heart-attack and now it is cancer that’s taking people’s lives. The worst part is that before killing people, this cancer business makes their lives miserable. The doctors try to prolong this misery as much as possible to milk more money and the Big Pharma benefits from it by selling more and more expensive drugs. The butcher doctors even prescribe drugs that they know are not going to work in a particular situation or stage of the disease, still they do prescribe them. It’s all about money.

Watch Out!
One-in-five men and one-in-six women
worldwide will develop cancer over the
course of their lifetime! – IARC

Ever wonder how these ‘experts’ (actually Big Pharma) predict the number of future patients and diseases? Easy! They manufacture drugs and sell it. Every drug has negative side-effects – every drug, without exception. They attack your liver, kidneys, lungs, heart and above all your immune system – your defense wall. Millions of drug-doses make millions of new patients of new diseases (caused by the side-effects) every year and then the numbers expand – and so does the profits for the Big Pharma. All doctors work for them, directly or indirectly, getting commissions, percentage or kickbacks. Once you walk in their clinics, you cannot walk out 100% healthy – never!

Whistle-blowers have taken the risk and come forward to tell people that cancer has become an industry – 3 trillion dollar business every year – that offers big profits. It is not about curing the disease; it is about prolonging it and making maximum profits. Drug companies (pharmaceuticals) are making billions of dollars profits every year, even when the economy is in crisis. What happens to the suffering humanity in the process is not their problem; it’s yours. So, handle it the way you want.

Captain Dale Black was an airline pilot. His wife got cancer and over the years he became a researcher. He talks from his personal experience and research he did in this field. He says that cancer is not a disease; it’s big business!


“Cancer is not a disease; It’s Big Business!”
-- Capt. Dale Black
“Finally, there's hope for cancer patients. Cancer, all forms of cancer, doesn't just fall from the sky. Generally speaking, we give cancer to ourselves by the way we think, eat, drink and by how we deal with stress. In other words, how we LIVE. Cancer is preventable. Cancer is reversible. There is hope for cancer patients. Watch and learn.” (This particular video is intended only for adults with cancer).

***************************************
Butchers of Big Pharma
slaughter people every day
in the name of cancer treatment
to make big money! Drugs spread
diseases and offer no cure!

“I worked in an industry, the Pharmaceutical
Industry that do nothing, but annihilate the
population of this world. They kill more people
than wars we have in the world, but long term.
They punish you and then they kill you.”
– Dr. John R. Virapen

***************************************

The IARC – world cancer research agency – issued a report for 2018, with alarming facts and figures. Here are the excerpts:

Geneva, Switzerland, 12 September 2018 – New global cancer data suggests that the global cancer burden has risen to 18.1 million cases and 9.6 million cancer deaths.
The International Agency for Research on Cancer (IARC) estimate that one-in-five men and one-in-six women worldwide will develop cancer over the course of their lifetime, and that one-in-eight men and one-in-eleven women will die from their disease. A number of factors appear to be driving this increase, particularly a growing and ageing global population and an increase in exposure to cancer risk factors linked to social and economic development. For rapidly-growing economies, the data suggests a shift from poverty- or infection-related cancers to those associated with lifestyles more typical in industrialized countries.
There are some indications that scaled-up prevention efforts are starting to reduce cancer incidence rates, for example lower lung cancer incidence in men in Northern Europe and North America, or in cervical cancer across most regions except Sub-Saharan Africa compared to 2012 data. 

However countries are facing an overall increase in the absolute number of cancer cases. Asia accounts for nearly half of the new cancer cases and more than half of cancer deaths.

Estimated suggest that Asia and Africa have a higher proportion of cancer deaths (7.3% and 57.3% respectively) compared with their incidence (5.8% and 48.4% respectively). IARC suggests this trend is likely due to the higher frequency of cancer types associated with poorer prognosis, along with limited access to timely diagnosis and treatment. The 2018 data also suggests that countries with high Human Development Index (HDI) have 2-3 times higher cancer incidence than those with low or medium HDI.

Clear call for action
It is clear that cancer is an urgent global challenge and Governments must take measures to scale up prevention, early detection and diagnosis, treatment, and care services. The global cancer community has an important role to play in holding Governments accountable to their commitments and advocating for accelerated and evidence-based action nationally. 
One of the key concerns raised by IARC is that lung cancer is the leading cause of death globally and its prevalence is rising amongst women, surpassing breast cancers in 28 countries.


Excerpts from a New York Times report:
Feeding the Cancer Machine
By Shannon Brownlee

HAVE you ever wondered why hospitals offer free cancer screening tests? You’ve heard the ads on radio, and seen them in newspapers, urging you to come to your local hospital for a free Pap smear, mammogram or prostate cancer blood test.
Hospitals would like you to think they are doing this out of the goodness of their hearts, that free cancer screening is a public service intended solely to improve your health. But there may be another motive at work here: providing free screening brings in new cancer patients, and cancer generates profits.
Has the profit motive gotten in the way of finding a cure for cancer or better treatment? Could it be that at least some of the $100 billion we spend each year on detecting and treating this disease is used not to improve the health of patients, but rather to prop up hospital finances?
Cancer makes money for hospitals in a couple of ways. First, it’s a disease of aging, and that means the majority of people who get it are covered by Medicare, which always pays its bills. Second, many treatments for cancer patients are particularly profitable, especially compared to those for other diseases.
Hospitals generally make money on surgery to remove cancer. Then there are all the imaging tests, like CT scans and M.R.I.’s, which are also well reimbursed by Medicare and other payers. The more cancer patients a hospital can attract, the faster it can recoup capital investments in imaging machines.
Another big source of profit is cancer drugs. Worldwide, we spend about $35 billion a year on chemotherapy and other drugs related to cancer treatment. Hospitals make money on drugs by purchasing wholesale and charging insurers full price. Cancer doctors also purchase drugs wholesale, making as much as two-thirds of their income on the “chemotherapy concession,” in which they sell and administer chemotherapy drugs in their offices.

Hospitals and doctors need to make money, of course, but the high profit margin in cancer has created a situation where providers have every reason to screen more people and treat those who are diagnosed with cancer more aggressively — and few incentives to hold back, even if that’s what the patient might prefer. Recognizing this, Medicare reduced its reimbursements for chemotherapy in 2005, but even with those changes, cancer remains an enormous economic engine in our health care system.
Sure, aggressive treatment is reducing mortality and improving the quality of life for some patients. Sometimes it even cures. But for many others, the cancer machine offers only marginal benefits at best, and providers push screening and aggressive treatment in part because they have nothing else to give, but also because it’s profitable. How much of the money we spend on unnecessary or futile cancer treatment might be put to better use searching for real advances?


Chemotherapy warning as hundreds die
from cancer-fighting drugs 
By Sarah Knapton, Science Editor, The Telegraph (pub. 30 August 2016)

Patients should be warned about the dangers of chemotherapy after research showed that cancer drugs are killing up to 50 per cent of patients in some hospitals.
For the first time researchers looked at the numbers of cancer patients who died within 30 days of starting chemotherapy, which indicates that the medication is the cause of death, rather than the cancer.
The study by Public Health England and Cancer Research UK found that across England around 8.4 per cent of patients with lung cancer, and 2.4 per cent of breast cancer patients died within a month.
But in some hospitals the figure was far higher. In Milton Keynes the death rate for lung cancer treatment was 50.9 per cent, although it was based on a very small number of patients.  
At Lancashire Teaching Hospitals the 30 day mortality rate was 28 per cent for palliative chemotherapy for lung cancer, which is given when a cure is not expected and treatment given to alleviate symptoms.  

Deaths of lung cancer patients from chemotherapy were also far higher than the national average in Blackpool, Coventry, Derby, South Tyneside and Surrey and Sussex, according to the research. 
Similarly, around one in five people who underwent palliative care for breast cancer at Cambridge University Hospitals died from their treatment. 

The study looked at more than 23,000 women with breast cancer and nearly 10,000 men with 9634 non-small cell lung cancer who underwent chemotherapy in 2014. Of those treated 1,383 died within 30 days. 

Chemotherapy is toxic for the body because it does not discriminate between healthy and cancerous cells. 
The researchers also found that there were significant differences in survival for older people and those in poorer health. They advised doctors to be more careful in selecting patients for treatment where it could do more harm than good.
Professor David Dodwell, Institute of Oncology, St James Hospital, Leeds, UK, says:
“I think it’s important to make patients aware that there are potentially life threatening downsides to chemotherapy. And doctors should be more careful about who they treat with chemotherapy.”

Professor David Cameron, Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, added: “The concern is that some of the patients dying within 30 days of being given chemo probably shouldn’t have been given the chemo. But, how many? There is no easy way to answer that, but perhaps looking at those places/hospitals where the death rate was higher might help. 
The research was published in The Lancet Oncology.



The Cancer Industry Expects 1.7 million New Cancer Cases in the US for 2019

Corporate healthcare policies are based on real world figures and estimates based on actions taken from previous fiscal years, e.g. mass vaccinations. It is estimated that more than 1.7 million new cancer cases are expected to be diagnosed in 2019, according to the data published by the American Cancer Society this year.

This estimate, according to the same report, does not include carcinoma in situ (noninvasive cancer) of any site except urinary bladder, nor does it include basal cell or squamous cell skin cancers because these are not required to be reported to cancer registries. In short, there will be more than they could feast upon as the days go by.

How many will die of cancer this year?
About 606,880 Americans are expected to die of cancer in 2019, which translates to about 1,660 deaths per day.

Cancer is the second most common cause of death in the US, exceeded only by heart disease. All of these figures can help in the determination of pricing of medical goods and services, and the exact amount of investments in the building of new hospitals and morgues across the different states. The rest will be budgeted for public relations and medical incentives for all professional medical practitioners who are devoutly
participating in the real world hunger games.


As of today, the top 6 pharmaceutical stocks that you can buy shares from are the following:

Eli Lilly & Co. (LLY)
Market Cap: $124.73 billion
Performance: 35.6% annual return

Merck & Co., Inc. (MRK)
Market Cap: $196.84 billion
Performance: 34.5%  annual return

Pfizer Inc. (PFE)
Market Cap: $227.87 billion
Performance:18.7% annual return

Zoetis Inc. (ZTS)
Market Cap: $48.98 billion
Performance: 17.7%  annual return

Johnson & Johnson (JNJ)
Market Cap: $375.67 billion
Performance: -7.3%  annual return

AbbVie Inc. (ABBV)
Market Cap: $116.53 billion
Performance: -9.33%  annual return

Eli Lilly is where Dr. John Rengen Virapen used to work for the better part of his life. It was the birth of his own son that changed it all.
“I worked in an industry, the Pharmaceutical Industry that do nothing, but annihilate the population of this word. They kill more people than wars we have in the world, but long term. They punish you and then they kill you.” – Dr. John R. Virapen

Whether one dies or cured of cancer, both scenarios are always unwelcomed. The primary objective is to prolong the agony, as much as possible, which explains the contradicting prescriptions of hazardous chemo, sodium bicarbonate, and a load of multi-vitamins.


According to a peer-reviewed study, a majority of patients (51.3%) received conflicting medication information that had a direct negative effect on medication adherence. Cancer takes about 10 years to develop from the time of infection, whether induced or consequential. The 10-year lead-time is a strong manifestation of the resiliency and competence of the autoimmune system without any form of intervention.

If each of the estimated 1.7 million new cancer cases spends $250,000 for cancer treatment, a whopping $425 billion can be generated in the US alone. But this estimate is too conservative considering that in the year 2017 alone, the U.S. health care spending grew by 3.9 percent, reaching $3.5 trillion or $10,739 per person.
That is, of course, a combined figure of expenditures for all types of health conditions from The National Health Expenditure Accounts (NHEA).

Globally, the total health expenditures in 2015 alone is pegged at $7.2 trillion. About half of that amount was spent by the Americans, which makes them the most chemically and financially devastated population on the planet.

All of the above numbers continue to feed the corrosive system in spite of the growing number of independent companies promoting alternative approaches to healthcare.
Imagine if, instead of poisoning ourselves with toxic chemicals that have no useful purpose in our body, we spent the $7.2 trillion on the implementation of better technologies, new infrastructures, housing and new industries, we could have dotted this planet with beautiful, sustainable cities and better societies, a long time ago.

***************

No comments:

Post a Comment

Note: only a member of this blog may post a comment.